Sentences with phrase «lymphoma patients treated»

High serum vascular endothelial growth factor level is an adverse prognostic factor for high - risk diffuse large B - cell lymphoma patients treated with dose - dense chemoimmunotherapy.

Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.

Not exact matches

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

The first gene therapies approved in the United States are treating patients with certain types of leukemia and lymphoma.

«That's because we desperately need a new strategy to treat this lymphoma — many patients are resistant to currently available treatments,» says the study's senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology / Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell.

With that idea in mind, Karmali is leading an innovative Phase II clinical trial evaluating the effectiveness of combining the diabetes medication metformin with standard chemotherapy to treat patients with diffuse large B - cell lymphoma.

From patient medical records, they obtained detailed information on treatments, which they used to estimate radiation doses to the stomach and to calculate the doses and types of chemotherapy that were used to treat the survivors» Hodgkin lymphoma.

The approach, which is described in a paper to be published September 7 in The Journal of Experimental Medicine, could allow those in need of such transplants, including leukemia and lymphoma patients, to be treated with fewer donor stem cells while limiting potential adverse side effects.

In the trial, co-led by Rachael Clark, MD, PhD, associate professor of Dermatology at Harvard Medical School, Alain Rook, MD, professor of Dermatology and director of the Cutaneous Lymphoma Program at Penn Medicine, and Joel M. Gelfand, MD, MSCE, associate professor of Dermatology and medical director of the Clinical Studies Unit at Penn Medicine, twelve patients who had previously undergone an average of six treatments for early stage CTCL were treated with topical resiquimod gel at varying doses and intervals.

Professor Chris Bunce, Research Director at leukemia & Lymphoma Research, said: «Targeted drugs, like monoclonal antibodies, have shown great promise in recent years in effectively treating a patient's disease while minimising side effects.

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL)-- a rare type of non-Hodgkin lymphoma that affects the skin.

Though unintentional, Ding said the analysis provides an explanation for why investigational drugs that inhibit a protein called BTK have been effective in treating patients with lymphoma.

A unique approach to targeting the abnormal T - cells that cause T - cell lymphomas could offer hope to patients with the aggressive and difficult - to - treat family of cancers, finds a study involving researchers from Cardiff University.

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B - Cell Lymphoma (DLBCL) Patients Treated with Dose - Dense Chemoimmunotherapy and Systemic CNS Prophylaxis.

Shah noted that cerebral edema has also been observed in clinical trials — among 6 ALL patients participating in the JUNO trials (and in 1 patient with non-Hodgkin lymphoma treated in the ZUMA - 1 phase II registration trial).

One patient treated for extensive chronic GVHD showed a transient response in the liver, but not in the skin and he died of Epstein - Barr virus lymphoma.

Brentuximab vedotin was previously approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.

The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.

Dumler was only the second patient at MD Anderson and the third in the world to receive CAR T cells to treat non-Hodgkin's lymphoma on the multicenter clinical trial.

Wharam says a pediatric patient he treated for Hodgkin's lymphoma highlights the paradox of these early radiation therapies in children.

It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T - cell approach that is less toxic and does not require pretreatment chemotherapy.

The percentage of Hodgkin lymphoma and Wilms tumor patients treated with radiation fell from 96 to 77 percent and 77 to 49 percent respectively.

I was a medical oncologist and I was treating patients with lymphoma and breast cancer.

Ibrutinib is also approved to treat chronic lymphocytic leukemia / small lymphocytic lymphoma, including patients with 17p deletion, mantle cell lymphoma after at least one prior therapy, and patients with Waldenstrom macroglobulinemia.

Non-Hodgkin lymphoma patients are usually treated with rituximab (Rituxan ®, a monoclonal antibody) in combination with chemotherapy.

The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is approved to treat Hodgkin lymphoma in patients whose disease has failed to respond to other treatment and, as of August 2015, to prevent relapse following a stem cell transplant.

FDA Approved Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 therapy.

This agent was approved in October 2017 for the management of patients with previously treated large B - cell lymphomas, including diffuse large B - cell lymphoma (DLBCL).

Professional interests include osteosarcoma, lymphoma / leukemia, and novel therapeutics to treat cancer, radiation oncology, palliative care and maximizing cancer patients» quality of life.

Generally, a hematologist treats patients with blood disorders, such as types of hemophilia, leukemia, lymphoma, and sickle cell anemia.

Rituximab Improves Overall Survival in Patients Treated with CODOX - M / IVAC for Burkitt Lymphoma (BL) and B - Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B - Cell Lymphoma and BL (BCL - U): A Single Center Experience and Review of the Literature